- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04483752
Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images (PREDISCAN)
The main differences observed between SARSCoV-2 pneumonia and other epidemic viral pneumopathies (e.g., seasonal influenza) are the greater infectivity of SARSCoV-2, the clinical severity of the disease, particularly in young patients without co-morbidities, and the observation of radiological images related to significant parenchymal aggression in a large number of patients.
The lesions in the acute phase correspond essentially to bilateral ground glass opacity more or less associated with condensations which would be markers of more severe infections.
The major scope of the lesions in the acute phase raises the question of whether or not the scanning anomalies are completely resolved over time, and the possible impact on lung function. This risk of sequelae is very important to study given the large number of patients affected by SARSCoV-2, especially since these are often young patients who appear to be "healthy".
In the current context of the CoV-2 SARS pandemic, the improved quality and availability of diagnostic scanners provides a wealth of information on the semiology and progression of lung disease with minimal exposure to ionizing radiation. A majority of hospitalized patients with SARSCoV-2 received a CT scan in the early phase of the disease. Indeed, the French Society of Radiology has recommended the performance of a CT scan without injection in thin sections in case of suspicion or for confirmation of the diagnosis in patients presenting initial or secondary clinical signs of severity and justifying hospital management due to the initial lack of reagents for performing biological tests (RT-PCR) and the high sensitivity of the CT scan and its specificity in epidemic periods.
The present study aims to study the kinetics of lung involvement in SARS CoV 2, to study the predictive character of the chest CT scan performed at the patient's discharge on the existence of radiological sequelae at 3 months but also at 1 year in order not to misunderstand the constitution of late fibrosis after partial resolution of the CT images. The investigatos will study the correlation between possible radiological abnormalities and the clinical presentation (patient symptoms and lung function). The rigorous follow-up of these patients will allow us to set up, if necessary, early treatment of the detected abnormalities (inhaled corticoids in case of bronchial or bronchiolar damage, study of the place of an anti-fibrosis treatment in case of fibrosis,...).
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: CAROLINE CARAMELLA, MD
- Phone Number: 01.40.94.85.71
- Email: a.caramella@hml.fr
Study Locations
-
-
-
Le Plessis-Robinson, France, 92350
- Recruiting
- Hopital Marie Lannelongue
-
Contact:
- CAROLINE CARAMELLA, MD
-
Paris, France, 75014
- Not yet recruiting
- Hôpital Saint Joseph
-
Contact:
- Marie De Torcy
-
Villejuif, France
- Not yet recruiting
- Institut Gustave Roussy (IGR)
-
Contact:
- Corinne Institut Gustave Roussy (IGR), MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient hospitalized for SARS CoV-2 infection proved by RT-PCR and/or by a typical SARS CoV-2 pneumonia clinic and imaging that required hospitalization Scan performed when the patient is no longer oxygenating, i.e. at least 48 hours prior to hospital discharge (discharge criterion) up to a maximum of 1 month after hospitalisation.
- Patient ≥ 18 years old
- Patient who has given free, informed and written consent
Exclusion Criteria:
- Patient ≤ 18 years old
- CT Contraindication
- Pregnant or breastfeeding woman
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Patients hospitalised for SARS CoV-2 infection.
|
Chest CTscan at 3 and 12 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
description of the different types of lesions
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
quantification of circulating antibodies and correlation between the level of immunization against SARS CoV2, the severity of the initial disease and the existence or not of long-term pulmonary sequelae
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-A01322-37
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CoV2 SARS Pneumonia
-
Collegium Medicum w BydgoszczyRecruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Meshalkin Research Institute of Pathology of CirculationUnknown
-
Collegium Medicum w BydgoszczyActive, not recruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
University Hospital, LilleCompleted
-
CHU de ReimsUnknownSevere SARS-CoV2 PneumoniaFrance
-
Università Politecnica delle MarcheUnknown
-
BioNTech SECompletedCOVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)United States, Germany, Turkey, South Africa
-
Hospital Ambroise Paré ParisEnrolling by invitationCOVID | Sars-CoV2France
-
Andalusian Network for Design and Translation of...Completed
Clinical Trials on CHEST CT SCAN
-
Research and Practical Clinical Center for Diagnostics...CompletedCoronavirus Infections | PneumoniaRussian Federation
-
Jessica SierenVida Diagnostics, IncNot yet recruitingChronic Obstructive Pulmonary Disease | Pulmonary Disease | Cancer, Lung
-
Assistance Publique - Hôpitaux de ParisCompletedDyspnea | Community-acquired PneumoniaFrance
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalCompletedLung CancerUnited States
-
Centre Hospitalier Universitaire de NiceActive, not recruitingOsteoporosis | Interstitial Lung Disease | Vertebral FractureFrance
-
CHU de ReimsRecruitingPrimary Immunodeficiency | Common Variable Immunodeficiency | Igg Subclass Deficiency | Selective IgM DeficiencyFrance
-
Istituto Clinico HumanitasRecruitingTracheal StenosisItaly
-
Hospital St. Joseph, Marseille, FranceRecruiting
-
Seoul National University HospitalCompletedLatent TuberculosisKorea, Republic of
-
University of PittsburghCompleted